cyclooxygenas
cox
prostaglandin
e
pge
signal
pathway
known
modul
varieti
homeostat
process
involv
variou
pathophysiolog
condit
coxspg
signal
pathway
also
demonstr
provir
antivir
effect
appear
differ
even
viru
famili
porcin
sapoviru
cowden
strain
member
genu
sapoviru
within
calicivirida
famili
induc
strong
transient
signal
enhanc
viru
replic
howev
whether
infect
virus
differ
genera
activ
coxspg
signal
thu
affect
replic
virus
remain
unknown
present
studi
infect
cell
felin
caliciviru
fcv
strain
genu
vesiviru
murin
noroviru
mnv
strain
genu
noroviru
activ
signal
timedepend
manner
treatment
pharmacolog
inhibitor
transfect
small
interf
rna
sirna
enzym
significantli
reduc
product
pge
well
fcv
mnv
replic
inhibitori
effect
pharmacolog
inhibitor
enzym
replic
virus
restor
addit
pge
silenc
via
sirna
inhibit
via
inhibitor
also
decreas
product
pge
replic
virus
attribut
inhibit
signal
pathway
data
indic
pge
signal
pathway
provir
effect
replic
fcv
mnv
pharmacolog
inhibitor
enzym
serv
potenti
therapeut
candid
treat
fcv
mnv
infect
calicivirida
famili
compos
small
nonenvelop
icosahedr
virus
possess
singlestrand
positivesens
rna
genom
kb
size
famili
compris
five
establish
genera
lagoviru
neboviru
noroviru
sapoviru
vesiviru
six
addit
unclassifi
new
genera
tent
name
recoviru
bavoviru
nacoviru
saloviru
sanoviru
valoviru
member
famili
import
pathogen
medic
veterinari
field
exampl
felin
caliciviru
fcv
belong
genu
vesiviru
caus
acut
selflin
oral
upper
respiratori
tract
diseas
cat
moreov
virul
system
fcv
mutant
strain
caus
sever
system
diseas
edemat
ulcer
skin
lesion
jaundic
high
mortal
recent
found
us
eu
porcin
sapoviru
psav
bovin
noroviru
neboviru
caus
widespread
acut
gastroenter
piglet
calv
respect
medic
field
human
noroviru
human
sapoviru
especi
former
lead
caus
gastroenter
human
account
death
per
annum
children
fcv
vaccin
avail
cat
howev
limit
efficaci
low
prevent
effect
fcv
differ
antigen
shortliv
immun
lack
robust
reproduc
vitro
cultiv
system
human
norovirus
hnov
develop
recent
therebi
hinder
develop
effect
intervent
therefor
understand
hnov
life
cycl
larg
base
surrog
virus
specif
murin
norovirus
mnv
therapeut
candid
fcv
mnv
may
util
variou
fcv
strain
hnov
cyclooxygenas
cox
enzym
convert
arachidon
acid
prostaglandin
pg
orchestr
varieti
homeostat
process
particip
variou
pathophysiolog
condit
inflamm
immun
respons
current
three
isoform
cox
identifi
studi
function
housekeep
isoform
cox
express
constitut
perform
function
control
renal
blood
flow
platelet
aggreg
provid
protect
stomach
ulcer
activ
respons
differ
extracellular
intracellular
stimuli
lead
accumul
pg
includ
pge
pge
commonli
involv
cellular
immun
inflamm
event
serv
strong
regul
cellcel
interact
cytokin
product
antigen
present
cell
differenti
surviv
apoptosi
cell
migrat
viral
infect
gener
impos
immunolog
pressur
host
turn
hinder
success
replic
evad
virus
devis
strategi
subvert
cellular
pathway
benefit
via
coxsprostaglandin
e
pge
signal
particip
modul
host
respons
infect
life
cycl
sever
virus
repres
least
eleven
differ
viru
famili
known
activ
coxspg
signal
enhanc
express
level
pge
calicivirida
arterivirida
herpesvirida
rhabdovirida
retrovirida
picornavirida
flavivirida
orthomyxovirida
adenovirida
paramyxovirida
virus
includ
vesicular
stomat
viru
vsv
enteroviru
dengu
viru
hepat
c
viru
hcv
japanes
enceph
viru
influenza
viru
cytomegaloviru
cmv
herp
simplex
viru
type
known
use
signal
pathway
benefit
rather
signal
pathway
howev
porcin
reproduct
respiratori
syndrom
prr
arteriviru
shown
hijack
signal
pathway
induc
fever
pseudorabi
herpesviru
shown
use
pathway
success
replic
contrast
vitro
andor
vivo
treatment
pge
reduc
replic
hepat
b
viru
adenovirus
parainfluenza
viru
measl
viru
suggest
antivir
function
pge
virus
moreov
cox
pge
signal
pathway
final
product
pge
shown
facilit
inhibit
replic
virus
famili
exampl
retrovirida
famili
coxspg
signal
pathway
andor
pge
enhanc
replic
bovin
leukemia
viru
well
human
tcell
leukemia
virusi
iii
inhibit
human
immunodefici
monocytederiv
macrophag
note
treatment
pge
enhanc
replic
tcell
line
indic
also
depend
cell
role
coxspg
signal
pathway
differ
viral
infect
previous
report
infect
psav
strain
cowden
induc
strong
signal
transient
signal
late
stage
infect
pharmacolog
inhibitor
sirna
significantli
reduc
psav
replic
restor
addit
pge
indic
coxspg
act
provir
signal
howev
role
coxspg
signal
unknown
member
within
calicivirida
famili
prompt
us
investig
whether
member
calicivirus
particular
fcv
mnv
strain
use
signal
pathway
regul
replic
demonstr
express
induc
fcv
mnv
infect
therebi
caus
surg
pge
level
furthermor
pharmacolog
inhibitor
sirna
enzym
significantli
reduc
pge
product
well
mnv
fcv
replic
could
restor
addit
pge
result
suggest
pathway
provir
effect
fcv
mnv
replic
mous
macrophag
crandel
ree
felin
kidney
crfk
cell
purchas
american
type
cultur
collect
atcc
manassa
vi
usa
routin
grown
dulbecco
modifi
eagl
minim
essenti
medium
dmem
supplement
fetal
bovin
serum
fb
uml
penicillin
streptomycin
fcv
strain
obtain
atcc
propag
crfk
cell
mnv
strain
kind
gift
dr
hw
virgin
washington
univers
school
medicin
usa
cesium
chlorid
cscl
densiti
gradient
ultracentrifug
perform
purifi
masscultur
strain
describ
previous
viral
titer
mnv
fcv
strain
determin
median
tissu
cultur
infecti
dose
tcid
unit
per
millilit
immunofluoresc
assay
respect
describ
purchas
cayman
chemic
ann
arbor
mi
usa
indomethacin
dimethyl
sulfoxid
dmso
sigmaaldrich
st
loui
mo
usa
sirna
compris
three
target
gene
scrambl
sirna
purchas
santa
cruz
biotechnolog
inc
dalla
tx
usa
synthet
pge
tocri
bioscienc
ellisvil
mo
usa
polyclon
antibodi
rabbit
monoclon
antibodi
mous
acquir
abcam
cambridg
usa
mous
monoclon
antibodi
fcv
capsid
protein
santa
cruz
biotechnolog
inc
rabbit
polyclon
mnv
vpg
antibodi
kind
gift
dr
goodfellow
cambridg
univers
uk
secondari
antibodi
use
horseradish
peroxidaseconjug
goat
immunoglobulin
rabbit
igg
cell
signal
beverli
usa
mous
igg
santa
cruz
fluorescein
isothiocyana
fitc
conjug
goat
immunoglobulin
rabbit
igg
mous
igg
jackson
immuno
research
laboratori
west
grove
pa
usa
cytotox
test
differ
chemic
use
carri
tetrazolium
bromid
mtt
assay
describ
previous
briefli
monolay
crfk
cell
grown
plate
incub
h
differ
concentr
chemic
remov
medium
wash
twice
phosphat
buffer
salin
pb
ph
mtt
solut
ad
well
incub
h
co
incub
next
dmso
ad
well
incub
min
room
temperatur
optic
densiti
od
determin
enzymelink
immunoabsorb
assay
elisa
reader
nm
calcul
percent
cell
viabil
determin
use
follow
formula
od
sampl
od
blank
od
control
od
blank
nontox
concentr
chemic
util
studi
inhibitor
chemic
use
studi
dilut
dmso
stock
concentr
mm
subsequ
dilut
media
make
work
solut
monolay
crfk
cell
grown
plate
treat
chemic
inhibitor
describ
previous
mocktreat
pretreat
posttreat
preposttreat
briefli
confluent
cell
pretreat
variou
concentr
inhibitor
h
infect
mnv
moi
tcid
ml
fcv
moi
ffuml
strain
pretreat
group
posttreat
group
cell
adsorb
mnv
moi
tcid
ml
fcv
moi
ffuml
strain
treat
differ
concentr
inhibitor
preposttreat
group
cell
pretreat
differ
concentr
inhibitor
h
adsorb
mnv
moi
tcid
ml
fcv
moi
ffuml
strain
treat
concentr
inhibitor
describ
cdna
partial
part
polymeras
fcv
strain
part
ntermin
open
read
frame
orf
mnv
strain
amplifi
convent
pcr
use
primer
list
tabl
dna
fragment
gel
purifi
use
sv
gel
pcr
cleanup
system
promega
fitchburg
wisconsin
usa
ligat
pgemteasi
vector
promega
sampl
transform
homemad
posit
coloni
pick
white
blue
screen
select
coloni
grown
lbmedium
contain
ampicillin
plasmid
purifi
use
hybridq
plasmid
rapidprep
kit
geneal
songpagu
seoul
south
korea
concentr
determin
spectrophotometri
biophotomet
plu
eppendorf
hamburg
germani
plasmid
fcv
mnv
strain
name
ptafcv
respect
mockor
virusinfect
mockor
inhibitortr
sirnatransfect
cell
wash
thrice
cold
pb
scrape
collect
clean
microtub
harvest
sampl
centrifug
g
min
total
rna
extract
use
purelink
rna
minikit
ambion
life
technolog
carlsbard
ca
usa
follow
manufactur
instruct
quantifi
genom
copi
number
fcv
mnv
strain
cell
treat
inhibitor
infect
strain
transfect
sirna
describ
freezethaw
three
time
cell
debri
remov
centrifug
g
min
sampl
immedi
process
store
use
total
rna
isol
supernat
use
viral
rna
extract
kit
bionner
daejeon
south
korea
follow
manufactur
instruct
concentr
extract
rna
calcul
spectrophotometri
nm
use
biophotomet
plu
eppendorf
onestep
realtim
rtpcr
qrtpcr
assay
primer
pair
specif
polymeras
fcv
mnv
perform
describ
previous
primer
pair
use
list
tabl
briefli
total
rna
isol
describ
harvest
sampl
subject
three
time
freezethaw
cycl
reaction
carri
use
corbett
research
rotorgen
realtim
amplif
system
corbett
research
mortlak
australia
lorox
one
step
kit
biolin
london
uk
next
qrtpcr
reaction
prepar
compos
rna
templat
sensifast
onestep
mixtur
forward
revers
primer
final
concentr
primer
pmole
revers
transcriptas
ribosaf
rnase
inhibitor
rnase
free
water
amplif
profil
fcv
follow
revers
transcript
min
polymeras
activ
min
cycl
amplif
consist
denatur
primer
anneal
extens
revers
transcript
carri
min
follow
polymeras
activ
min
initi
denatur
min
cycl
amplif
consist
denatur
primer
anneal
extens
copi
number
fcv
gene
calcul
use
dilut
known
concentr
vitro
transcrib
complementari
rna
use
ptafcv
plasmid
make
standard
curv
quantif
rna
sampl
calcul
use
rotorgen
corbett
research
mortlak
australia
determin
express
level
cox
gene
mock
viru
chemic
sirnatr
sampl
cell
harvest
total
rna
extract
describ
rna
concentr
determin
cdna
prepar
use
rna
revers
transcrib
use
random
hexam
roch
basel
switzerland
specif
primer
pair
qpcr
design
base
publish
sequenc
list
tabl
reaction
carri
total
volum
contain
pmole
forward
revers
primer
cdna
topreal
qpcr
premix
enzynom
daejon
south
korea
amplif
follow
initi
denatur
min
follow
cycl
denatur
primer
anneal
extens
rel
express
calcul
via
use
rotorgen
softwar
corbett
research
mortlak
australia
describ
previous
normal
sampl
actin
gene
tabl
quantifi
level
pge
determin
via
pge
eia
kit
cayman
chemic
ann
arbor
mi
usa
follow
manufactur
instruct
clarifi
supernat
collect
differ
time
point
cell
mockinfect
infect
viru
mocktreat
treat
chemic
scrambl
sirnatransfect
transfect
sirna
use
elisa
reader
absorb
read
nm
concentr
pge
calcul
comparison
standard
curv
median
tissu
cultur
infecti
dose
tcid
mnv
fcv
strain
sampl
obtain
experi
determin
describ
previous
briefli
serial
dilut
clarifi
supernat
prepar
confluent
crfk
cell
grown
plate
inocul
dilut
sampl
incub
co
incub
day
postinfect
viral
titer
calcul
use
reed
muench
method
express
tcid
ml
sirna
target
gene
scrambl
sirna
transfect
confluent
crfk
raw
cell
grown
plate
use
lipofectamin
reagent
invitrogen
carlsbad
ca
usa
accord
manufactur
instruct
cell
mockinfect
infect
fcv
moi
ffuml
mnv
moi
tcid
ml
strain
cell
subject
qpcr
tcid
ml
western
blot
analys
appropri
time
point
cell
experi
wash
harvest
lyse
differ
time
point
use
cell
extract
buffer
invitrogen
supplement
proteas
phosphatas
inhibitor
roch
denatur
cell
lysat
resolv
sodium
dodecyl
sulfat
sd
polyacrylamid
gel
transfer
nitrocellulos
blot
membran
amersham
protran
ge
healthcar
life
scienc
germani
membran
immunoblot
primari
antibodi
glyceraldehyd
dehydrogenas
gapdh
mnv
vpg
fcv
capsid
secondari
antibodi
specif
rabbit
mous
igg
ad
h
room
temperatur
develop
use
enhanc
chemiluminesc
reaction
kit
dogen
nowongu
seoul
south
korea
imag
captur
davinchwestern
imag
system
young
ltd
kangnam
seoul
south
korea
sampl
normal
correspond
gapdh
level
sampl
intens
protein
rel
gapdh
determin
densitometr
analysi
viral
titer
fcv
strain
determin
immunofluoresc
assay
describ
previous
briefli
confluent
crfk
cell
grown
plate
inocul
dilut
sampl
incub
co
incub
hpi
cell
fix
cold
aceton
cell
wash
pb
contain
new
fetal
bovin
serum
pbsfb
incub
antifcv
capsid
dilut
overnight
cell
wash
three
time
cold
pb
fitcconjug
goat
antimous
igg
molecular
probe
eugen
usa
secondari
antibodi
ad
incub
h
room
temperatur
afterward
slide
wash
three
time
cold
pb
mount
glycerol
pb
ph
fcv
titer
calcul
use
reed
muench
method
express
fluoresc
focu
unit
ffu
ml
infect
inhibitori
effect
inhibitor
sirna
determin
immunofluoresc
assay
describ
previous
briefli
cell
grown
chamber
glass
slide
treat
variou
inhibitor
transfect
sirna
infect
fcv
ffuml
mnv
moi
tcid
ml
strain
mention
cell
wash
three
time
cold
pb
fix
formaldehyd
pb
cell
permeabil
triton
incub
room
temperatur
min
wash
pb
contain
new
fetal
bovin
serum
pbsfb
incub
antimnv
vpg
dilut
antifcv
capsid
dilut
overnight
cell
wash
three
time
cold
pb
antirabbit
antimous
alexa
fluor
molecular
probe
eugen
usa
secondari
antibodi
ad
afterward
slide
mount
slowfad
gold
antifad
reagent
life
technolog
eugen
usa
contain
dapi
solut
nuclear
stain
visual
use
lsm
confoc
microscop
analyz
use
lsm
softwar
carl
zeiss
oberkochen
germani
previous
report
infect
llcpk
cell
psav
strain
cowden
strongli
activ
signal
pathway
transient
induc
signal
pathway
late
stage
infect
henc
examin
whether
fcv
mnv
strain
also
abil
activ
coxspg
signal
pathway
replic
investig
first
evalu
influenc
fcv
mnv
infect
cox
gene
protein
express
express
level
mrna
protein
gradual
increas
h
postinfect
hpi
fig
parallel
increas
fcv
viral
rna
synthesi
fig
protein
level
remain
unchang
fig
similarli
timedepend
increas
express
mrna
protein
level
observ
associ
increas
mnv
mrna
level
start
hpi
fig
express
level
mrna
protein
also
unaffect
mnv
infect
fig
sinc
pge
one
main
product
cox
enzym
also
assess
express
level
pge
fcv
mnv
infect
concurr
increas
level
mnv
fcv
infect
product
pge
also
elev
timedepend
manner
start
hpi
fcv
fig
hpi
mnv
fig
confirm
correl
increas
pge
fcvand
mnvmediat
induct
influenc
select
nonselect
cox
inhibitor
pge
express
investig
nontox
dose
use
studi
determin
mtt
assay
fig
select
inhibitor
select
inhibitor
nonselect
inhibitor
indomethacin
hamper
fcv
mediatedpg
induct
dosedepend
manner
ad
remov
viru
inoculum
posttreat
ad
viru
adsorpt
step
preposttreat
fig
similarli
addit
cox
inhibitor
remov
mnv
inoculum
entir
cours
mnv
infect
reduc
pge
level
fig
howev
pretreat
cell
consequ
remov
inhibitor
fcv
mnv
infect
lower
pge
level
due
revers
natur
inhibitor
fig
corrobor
influenc
cox
gene
product
pge
fcv
mnv
infect
effect
sirna
also
examin
raw
crfk
cell
transfect
sirna
gene
show
reduct
express
level
correspond
target
gene
fig
transfect
sirna
target
raw
crfk
cell
follow
fcv
mnv
infect
respect
significantli
reduc
amount
pge
releas
fig
result
confirm
induct
togeth
basal
express
account
increas
pge
fcv
mnvinfect
cell
assess
effect
cox
stimul
replic
fcv
mnv
strain
assess
impact
cox
inhibitor
fcv
mnv
replic
raw
mrna
express
level
gene
viral
rna
level
b
crfk
cell
infect
without
fcv
moi
ffucel
indic
time
point
determin
quantit
real
time
pcr
mrna
level
normal
mrna
illustr
fold
induct
mockinfect
cell
c
monolay
crfk
cell
infect
without
fcv
moi
tcid
ml
indic
time
point
level
gapdh
protein
analyz
western
blot
analysi
gapdh
use
load
control
intens
target
protein
rel
gapdh
determin
densitometr
analysi
indic
lane
pge
level
supernat
harvest
cell
infect
without
fcv
moi
ffucel
indic
time
point
analyz
elisa
level
pge
supernat
compar
mockand
fcvinfect
group
data
shown
three
independ
experi
present
mean
standard
error
mean
statist
differ
evalu
oneway
analysi
varianc
p
p
p
http
cell
pretreat
pre
posttreat
post
preposttr
prepost
cox
inhibitor
viral
replic
monitor
hpi
fcv
hpi
mnv
examin
viral
titer
rna
level
select
inhibitor
reduc
level
infecti
viru
log
fcv
fig
log
mnv
fig
ad
infect
posttreat
maintain
throughout
viru
infect
preposttreat
convers
addit
select
inhibitor
follow
remov
viru
inoculum
posttreat
entir
progress
infect
preposttreat
caus
signific
reduct
fcv
log
infecti
viru
viral
rna
fig
mnv
infecti
viral
titer
genom
copi
number
log
fig
indomethacin
nonselect
cox
inhibitor
show
signific
effect
mnv
infect
lead
log
reduct
viru
yield
rna
synthesi
fig
fcv
infect
elicit
log
decreas
infecti
viral
titer
genom
copi
number
fig
ad
viru
adsorpt
maintain
throughout
cours
infect
signific
effect
fcv
mnv
replic
cell
pretreat
cox
inhibitor
fig
also
assess
effect
coxspecif
sirna
fcv
mnv
replic
fcv
genom
copi
number
titer
strongli
reduc
log
cell
transfect
sirna
cell
transfect
sirna
log
fig
transfect
sirna
result
similar
substanti
reduct
mnv
replic
caus
log
decreas
infecti
viral
titer
rna
level
fig
assess
effect
cox
inhibitor
fcv
mnv
replic
also
analyz
viral
protein
level
preand
posttreat
group
consist
result
reduc
product
fcv
capsid
protein
observ
posttreat
cox
inhibitor
dosedepend
manner
show
stronger
antifcv
effect
inhibitor
fig
express
level
mnv
vpg
protein
decreas
inhibitori
effect
drug
viru
titer
genom
copi
number
compar
mockand
drugtreat
group
g
h
scrambl
scram
sirna
transfect
crfk
cell
infect
fcv
moi
ffucel
sampl
harvest
hpi
viral
titer
genom
copi
number
determin
tcid
ml
g
qrtpcr
h
analys
three
independ
experi
conduct
present
due
cox
inhibitor
dosedepend
manner
particularli
posttreat
indomethacin
fig
transfect
sirna
result
lower
protein
induct
fcvand
mnvinfect
cell
fig
furthermor
treatment
crfk
cell
transfect
specif
sirna
caus
signific
decreas
number
fcv
antigenposit
cell
fig
similarli
reduc
number
mnv
antigenposit
cell
also
observ
cell
treat
transfect
specif
sirna
fig
togeth
result
suggest
augment
fcv
mnv
replic
possibl
relat
increas
level
pge
studi
provir
effect
coxspg
induct
fcv
mnv
infect
assess
whether
addit
exogen
pge
restor
inhibitori
effect
cox
inhibitor
viral
replic
select
inhibitor
use
fcv
nonselect
inhibitor
indomethacin
use
mnv
show
strong
inhibitori
effect
compar
cox
inhibitor
noncytotox
dose
coxinhibitor
combin
exogen
pge
use
experi
addit
pge
lead
restor
fcv
mnv
progeni
product
viral
rna
level
dosedepend
manner
fig
collect
result
confirm
pge
final
product
cox
enzym
mediat
provir
effect
fcv
mnv
replic
depend
virus
coxspg
signal
pathway
use
differ
pge
prr
arteriviru
mani
virus
pseudorabi
herpesviru
present
studi
fcv
mnv
strongli
activ
pathway
earli
replic
time
point
result
differ
previou
find
psav
strain
cowden
belong
calicivirida
famili
induc
late
activ
signal
pathway
suggest
activ
time
signal
pathway
differ
even
calicivirida
famili
addit
psav
cowden
strain
transient
activ
signal
later
stage
infect
interestingli
increas
mrna
protein
level
observ
entir
fcv
mnv
infect
howev
silenc
specif
sirna
well
inhibit
specif
inhibitor
decreas
product
pge
replic
virus
although
detail
mechan
result
unknown
presum
inhibit
basal
express
level
specif
inhibitor
sirna
suppress
pge
product
therebi
replic
virus
base
result
could
conclud
unlik
psavinduc
late
activ
signal
pathway
fcv
mnv
activ
signal
pathway
earli
replic
might
import
factor
success
replic
fcv
mnv
relat
viru
replic
coxpg
signal
pathway
provir
antivir
effect
present
mean
standard
error
mean
statist
differ
determin
use
oneway
analysi
varianc
p
p
p
http
pathway
enhanc
fcv
mnv
replic
inhibitori
effect
drug
viral
titer
genom
copi
number
compar
mockand
studi
inhibit
silenc
reduc
replic
fcv
mnv
moreov
reduc
viral
replic
cox
inhibitor
restor
addit
pge
similar
result
recent
report
psav
infect
studi
data
indic
like
psav
fcvand
mnvinduc
activ
signal
pathway
act
provir
mechan
replic
fcv
mnv
nonsteroid
antiinflammatori
drug
nsaid
target
cox
enzym
one
wide
prescrib
drug
due
analges
effect
potent
antiinflammatori
antipyret
properti
western
world
nsaid
report
potenti
therapeut
drug
viral
infect
exampl
pharmacolog
use
inhibitor
combin
neuraminidas
inhibitor
enhanc
surviv
mice
infect
influenza
select
inhibitor
shown
protect
mice
succumb
dengu
infect
studi
determin
potenc
differ
cox
inhibitor
fcv
mnv
infect
fcv
infect
select
inhibitor
log
suppress
fcv
titer
compar
inhibitor
among
cox
inhibitor
test
mnv
indomethacin
nonselect
cox
inhibitor
show
stronger
antimnv
effect
inhibitor
lead
log
decreas
mnv
titer
result
suggest
cox
inhibitor
potenti
drugtreat
group
g
h
scrambl
scram
sirna
transfect
cell
infect
mnv
moi
tcid
ml
sampl
harvest
hpi
viru
titer
genom
copi
number
determin
tcid
ml
g
qrtpcr
h
analys
inhibitori
effect
sirna
viral
titer
genom
copi
number
compar
mockand
sirnatransfect
group
three
independ
experi
conduct
present
mean
standard
error
mean
statist
differ
determin
use
oneway
analysi
varianc
p
p
http
candid
treatment
fcv
infect
particularli
seriou
problem
cat
futur
studi
need
determin
whether
vivo
treatment
cox
inhibitor
effect
treat
fcv
mnv
infect
nitric
oxid
shown
exert
antivir
effect
viru
infect
also
shown
coxpg
signal
pathway
also
regul
induc
nitric
oxid
synthas
enzym
respons
product
vitro
vivo
vesicular
stomat
viru
infect
shown
activ
signal
pathway
turn
restrict
product
way
demonstr
psavinduc
activ
signal
pathway
inhibit
product
favor
psav
replic
similar
respons
expect
fcv
mnv
infect
ongo
goal
futur
studi
case
viral
protein
could
activ
coxpg
signal
either
directli
indirectli
transcript
transactiv
gene
express
exampl
hcv
protein
known
enhanc
pathway
activ
multipl
signal
pathway
sever
acut
respiratori
syndrom
coronaviru
infect
viral
nucleocapsid
protein
activ
pathway
direct
bind
regulatori
element
ccaatenhanc
bind
protein
previou
report
psav
vpg
propol
protein
significantli
enhanc
express
signal
pathway
likewis
fcv
mnv
protein
anticip
activ
signal
pathway
mechan
investig
futur
studi
conclus
result
denot
crucial
role
signal
pathway
success
replic
fcv
mnv
creat
cellular
environ
suitabl
